CROs keep growing, as Tigermed acquires Tokyo firm

31 July 2024

Tigermed (SZ: 300347), a global clinical research solution provider, has completed a move to boost capabilities in Japan and beyond, with the acquisition of the contract research organization (CRO) Medical Edge.

Founded in 2015, Medical Edge specializes in data management, biostatistics and electronic data capture systems.

Following the buy, the firm will become a wholly-owned subsidiary of Tigermed Japan. Tigermed plans to leverage the broader customer base and brand to expand its R&D services in the Asia-Pacific region.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK